BackSonnet BioTherapeutics Holdings Overview

Sonnet BioTherapeutics Holdings Other Current Liabilities

Latest other current liabilities for SONN: $1.1M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$1.11M
17.57% YoYΔ $165586.00 vs prior year quarter

Peer average

Loading

Sonnet BioTherapeutics Holdings Other Current Liabilities History

Loading

Sonnet BioTherapeutics Holdings vs. peers: Other Current Liabilities Comparison

Loading

Sonnet BioTherapeutics Holdings Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Sonnet BioTherapeutics Holdings (SONN) FAQ

As of the most recent data (September 2025), SONN shows a other current liabilities of $1.1M. That compares with $940K in the prior-year period — up 17.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, SONN's other current liabilities is now $1.1M (was $940K) — a 17.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Sonnet BioTherapeutics Holdings is outperforming or lagging.

Tracking SONN's other current liabilities over time shows whether Sonnet BioTherapeutics Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $1.1M That compares with $940K in the prior-year period — up 17.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current liabilities page, Stockcircle has Sonnet BioTherapeutics Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current liabilities (currently $1.1M) with ownership activity and broader fundamentals.

Sonnet BioTherapeutics Holdings's other current liabilities is $1.1M; compare it with other Consumer Staples names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.